Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 12Breast Neoplasms 11Prostatic Neoplasms 10Glioblastoma 10Oropharyngeal Neoplasms 7Rectal Neoplasms 6Neoplasms 6Lung Neoplasms 6Astrocytoma 6Squamous Cell Carcinoma of Head and Neck 5Urinary Bladder Neoplasms 4Burkitt Lymphoma 4Adenocarcinoma of Lung 4Pancreatic Neoplasms 3Nasopharyngeal Carcinoma 3Mouth Neoplasms 3Lymphoma, Follicular 3Hodgkin Disease 3Gliosarcoma 3Glioma 3Esophageal Neoplasms 3Carcinoma, Squamous Cell 3Carcinoma 3Triple Negative Breast Neoplasms 2Sarcoma 2Rhabdomyosarcoma 2Neoplasm, Residual 2Mesothelioma, Malignant 2Meningeal Carcinomatosis 2Lymphoma, Large B-Cell, Diffuse 2

Interventions

cemiplimab 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sinonasal Squamous Cell Carcinoma × Radiotherapy × 30 days × Clear all
NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡